SRPT · Insider Trading
Sarepta Therapeutics,, Inc. Common Stock
Every open-market purchase and sale reported by SRPT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Ryan Ho-Yan Wong | Chief Financial Officer | F | −13,272 | −$294.90K |
| 2026-09-08 | Ian Michael Estepan | Chief Operating Officer | F | −24,799 | −$551.03K |
| 2026-09-08 | Cristin Rothfuss | EVP, General Counsel | F | −22,025 | −$489.40K |
| 2026-09-08 | Louise Rodino-Klapac | President, R&D and Tech Ops | F | −21,423 | −$476.02K |
| 2026-07-29 | Michael Severino | Chief Executive Officer | A | +756,104 | — |
| 2026-06-05 | Richard Barry | Director | A | +16,875 | — |
| 2026-06-05 | Michael Andrew Chambers | Director | A | +16,875 | — |
| 2026-06-05 | Claude Nicaise | Director | A | +16,875 | — |
| 2026-06-05 | Deirdre P Connelly | Director | A | +16,875 | — |
| 2026-06-05 | M Kathleen Behrens | Director | A | +16,875 | — |
| 2026-06-05 | Hans Lennart Rudolf Wigzell | Director | A | +16,875 | — |
| 2026-06-05 | Stephen Mayo | Director | A | +16,875 | — |
| 2026-06-05 | Kathryn Jean Boor | Director | A | +16,875 | — |
| 2026-03-13 | Cristin Rothfuss | EVP, General Counsel | F | −974 | −$16.59K |
| 2026-03-13 | Stephen Mayo | Director | Sell | −7,239 | −$123.21K |
| 2026-03-13 | Louise Rodino-Klapac | President, R&D and Tech Ops | F | −948 | −$16.14K |
| 2026-03-13 | Ryan Ho-Yan Wong | Chief Financial Officer | F | −256 | −$4.36K |
| 2026-03-13 | Ian Michael Estepan | Chief Operating Officer | F | −1,097 | −$18.68K |
| 2026-03-11 | Ian Michael Estepan | Chief Operating Officer | F | −1,619 | −$27.44K |
| 2026-03-11 | Louise Rodino-Klapac | President, R&D and Tech Ops | F | −1,399 | −$23.71K |
| 2026-03-11 | Cristin Rothfuss | EVP, General Counsel | F | −830 | −$14.07K |
| 2026-03-11 | Ryan Ho-Yan Wong | Chief Financial Officer | F | −275 | −$4.66K |
| 2026-03-03 | Louise Rodino-Klapac | President, R&D and Tech Ops | MIXED | +3,640 | −$72.66K |
| 2026-03-03 | Ian Michael Estepan | Chief Operating Officer | MIXED | +3,949 | −$67.65K |
| 2026-03-03 | Ryan Ho-Yan Wong | Chief Financial Officer | F | −450 | −$7.29K |
| 2026-03-03 | Cristin Rothfuss | EVP, General Counsel | F | −408 | −$6.61K |
| 2026-03-02 | Ian Michael Estepan | Chief Operating Officer | M | +7,450 | +$102.14K |
| 2026-02-27 | Louise Rodino-Klapac | President, R&D and Tech Ops | A | +1,875 deriv. | — |
| 2026-02-27 | Ian Michael Estepan | Chief Operating Officer | A | +1,875 deriv. | — |
| 2026-01-29 | M Kathleen Behrens | Director | MIXED | +4,006 | −$17 |
| 2026-01-29 | Claude Nicaise | Director | MIXED | +3,720 | +$16 |
| 2025-12-19 | Michael Andrew Chambers | Director | MIXED | — | — |
| 2025-12-18 | Ian Michael Estepan | Chief Operating Officer | Sell | −13,187 | −$294.20K |
| 2025-12-10 | Ryan Ho-Yan Wong | Chief Financial Officer | F | −158 | −$3.31K |
| 2025-12-09 | Douglas S Ingram | Chief Executive Officer | A | +539,084 | — |
| 2025-12-02 | Cristin Rothfuss | EVP, General Counsel | F | −229 | −$4.84K |
| 2025-11-19 | Louise Rodino-Klapac | President, R&D and Tech Ops | F | −4,582 | −$84.40K |
| 2025-09-05 | Cristin Rothfuss | EVP, General Counsel | A | +118,875 | — |
| 2025-09-05 | Ian Michael Estepan | Chief Operating Officer | A | +143,875 | — |
| 2025-09-05 | Ryan Ho-Yan Wong | Chief Financial Officer | A | +118,875 | — |
| 2025-09-05 | Louise Rodino-Klapac | President, R&D and Tech Ops | A | +143,875 | — |
| 2025-08-06 | Louise Rodino-Klapac | President, R&D and Tech Ops | A | +6,250 deriv. | — |
| 2025-08-06 | Ian Michael Estepan | Chief Operating Officer | A | +6,250 deriv. | — |
| 2025-08-06 | Bilal Arif | Chief Tech Ops Officer | A | +6,250 deriv. | — |
| 2025-08-04 | Ryan Ho-Yan Wong | Chief Financial Officer | F | −327 | −$5.37K |
| 2025-05-19 | Richard Barry | Director | M | +12,350 | +$402.98K |
| 2025-05-15 | Richard Barry | Director | M | +20,246 | +$389.36K |
| 2025-03-13 | Claude Nicaise | Director | MIXED | +7,255 | −$2.80K |
| 2025-03-11 | M Kathleen Behrens | Director | A | +2,383 | — |
| 2025-03-11 | Claude Nicaise | Director | A | +2,383 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Richard Barry | Director | 2,993,542 | $53.08M |
| Michael Severino | Chief Executive Officer | 756,104 | $13.41M |
| Michael Andrew Chambers | Director | 504,027 | $8.94M |
| Douglas S Ingram | Chief Executive Officer | 440,307 | $7.81M |
| M Kathleen Behrens | Director | 224,357 | $3.98M |
| Louise Rodino-Klapac | President, R&D and Tech Ops | 203,900 | $3.62M |
| Ian Michael Estepan | Chief Operating Officer | 177,184 | $3.14M |
| Ryan Ho-Yan Wong | Chief Financial Officer | 121,792 | $2.16M |
| Cristin Rothfuss | EVP, General Counsel | 115,519 | $2.05M |
| Claude Nicaise | Director | 48,407 | $858.26K |
| Hans Lennart Rudolf Wigzell | Director | 42,098 | $746.40K |
| Dallan Murray | Chief Customer Officer | 33,659 | $596.77K |
| Bilal Arif | Chief Tech Ops Officer | 32,500 | $576.23K |
| Kathryn Jean Boor | Director | 25,138 | $445.70K |
| Deirdre P Connelly | Director | 22,100 | $391.83K |
| Stephen Mayo | Director | 18,640 | $330.49K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SRPT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.